ESMO Gynaecological Cancers Annual Congress is now in full swing. Licence official ESMO Gynaecological Cancers presentations for an extended audience, for your own website or via Springer Healthcare's user-friendly online formats. Contact us now for further information. Read more at https://lnkd.in/ebDhpcC4 #ESMO #ESMOGYN #Oncology
Springer Healthcare’s Post
More Relevant Posts
-
Last week we asked you about the particular pediatric brain tumor that Ojemda got approval from the FDA to treat recently. So, the right answer is 'Low-Grade Glioma (LGG)' Stay tuned for the next weekly poll! And, stay informed about the latest developments in the world of oncology! 🔬Learn more here: https://bit.ly/3v0joFa 💫 #Larvol #CancerResearch #OncologyDevelopments #Oncology
To view or add a comment, sign in
-
Our AI in Precision Oncology Summit is LIVE! Register for free right now to listen live from 11:00-4:00 EST or tune in afterward for our recorded sessions. Don’t miss out! Follow our AI in Precision Oncology journal page where we will be posting more regarding the Summit, as well as all the exciting developments with the publication for 2024. https://lnkd.in/eaKRsdi8 #aiapplications #cancerresearch #oncology #precisionmedicine #ai
To view or add a comment, sign in
-
From the earliest well-documented cases in 1844 to today's recent research and treatment options, the journey through myeloma's history is a testament to scientific progress and the enduring spirit of those affected. Still, multiple myeloma is the second most common blood cancer in the world. For insights into the latest in myeloma research, visit: https://lnkd.in/dYfjkAVd #MyelomaACTIONMonth #Myeloma #Oncology #OncologyCompass #CancerResearch #PatientCare
To view or add a comment, sign in
-
Conversion from Accelerated to full or traditional approval for selpercatinib for RET fusion thyroid cancer, based on additional single arm data, more ORR and Durability of response. Incredibly effective therapy with durable responses ranging from 80-90%! Kudos to FDA Oncology for thoughtful and patient centered approval paradigms (full approval based on single arm ORR data). Yet another precision medicine making a true impact for patients with this rare mutation.
BREAKING: The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer. #oncology #hncsm https://lnkd.in/eB4QjkHk
To view or add a comment, sign in
-
Health and Wellness Coach, Consultant Obstetrician and Gynaecologist, Infertility Specialist, Gynaec Laparoscopic Surgeon, PCOS Reversal Expert & Consultant and at DR BORKAR’S MOTHER CARE Hospital Ulwe Navi Mumbai.
Exciting discussions at the MOC Oncology Update 2024 on the scientific program focused on Gynaecological Cancers in panel discussion. Insightful learnings that are sure to contribute to advancements in the field. #OncologyUpdate #GynaecologicalCancers #medicalscience #drkrushnaborkar10x
To view or add a comment, sign in
-
It's out now in the Journal of Personalized Medicine MDPI our latest research article entitled "Misdiagnosis and Clinical Insights into Acral Amelanotic Melanoma—A Systematic Review". Read it: https://lnkd.in/dxUDyWtZ 📢 Please read and share MDPI #SkinCancer #MedicalResearch #Melanoma #Oncology
To view or add a comment, sign in
-
🚨In-Depth Insights from ESMO 2024! Prof Dr Antonio González Martín, Medical Oncologist at the University of Navarra, presents key findings from the PRIMA/ENGOT-OV26/GOG-3012 trial in high-grade ovarian cancer: - Niraparib provides sustained PFS benefit, particularly in HRd-positive patients. - OS data showed no significant differences between niraparib and placebo arms. - The safety profile remains consistent, with low rates of severe adverse events. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! European Society of Gynaecological Oncology #MediMix #ESMO2024 #GynaecologicalCancer #Oncology #OvarianCancer #CancerResearch #ClinicalTrials
To view or add a comment, sign in
-
Today is Gastrointestinal Stromal Tumor (GIST) Awareness Day. Let's raise awareness and support those affected by this rare cancer. Early detection and research are key to fighting GIST. #GISTAwareness #CancerResearch #EarlyDetection #OneCellDiagnostics #onecelldx #oncology #precisiononcology
To view or add a comment, sign in
-
🌟 New Episode Alert: "What's New Doc? in GU Cancer”. Join Prof Christof Vulsteke from AZ Maria Middelares Gent and Prof Emmanuel Seront from UCL Louvain as they delve into the four-year update of the CLEAR study. This pivotal research explores the efficacy of lenvatinib and pembrolizumab versus sunitinib in advanced renal cell carcinoma. 👇 Watch the full video link in the comments! #MediMix #GUOncology #RenalCellCarcinoma #OncologyUpdates
To view or add a comment, sign in
-
Dive into the forefront of cancer research with our on-demand webinar for liquid biopsies. Explore the latest in cDNA applications and clinical biomarker identification, providing a deeper understanding of their roles in precision medicine. This webinar is your gateway to cutting-edge insights and methodologies that are shaping the future of oncology research. Watch or download at your convenience and take your research to the next level! ➡️ https://bit.ly/49Gk95c #CancerResearch #cDNA #ClinicalBiomarkers #Oncology #LiquidBiopsy
To view or add a comment, sign in
12,948 followers